Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 20;73(suppl 1):e450s.
doi: 10.6061/clinics/2018/e450s.

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

Renata Rodrigues da Cunha Colombo Bonadio  1 , Rodrigo Nogueira Fogace  1 , Vanessa Costa Miranda  1 , Maria Del Pilar Estevez Diz  1
Affiliations
Review

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

Renata Rodrigues da Cunha Colombo Bonadio et al. Clinics (Sao Paulo). .

Abstract

Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and somatic mutations in other homologous recombination genes and epigenetic modifications, have also been implicated in homologous recombination deficiency. The epidemiology and implications of these other mechanisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Comprehension of the role of homologous recombination deficiency in ovarian cancer also allows the development of therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Li X, Heyer WD. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res. 2008;18((1)):99–113. doi: 10.1038/cr.2008.1. - DOI - PMC - PubMed
    1. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411((6835)):366–74. doi: 10.1038/35077232. - DOI - PubMed
    1. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12((5)):245–59. doi: 10.1097/GIM.0b013e3181d38f2f. - DOI - PubMed
    1. Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016;375((22)):2154–64. doi: 10.1056/NEJMoa1611310. - DOI - PubMed
    1. Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaãa J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33((3)):244–50. doi: 10.1200/JCO.2014.56.2728. - DOI - PMC - PubMed

MeSH terms

Substances